Breaking News

Welton Pharma Licenses Lubrizol’s Apisolex Excipient for Cancer Therapy

Will use Apisolex excipient to increase solubility of formulation for SN-38 to treat colorectal and associated gastro-intestinal cancers.

The Lubrizol Corp. will license its novel excipient polymer technology, Apisolex excipient, to Welton Pharma. Welton will have access to use the Apisolex excipient to develop and commercialize a novel formulation of SN-38 to treat colorectal and associated gastro-intestinal cancers. Introduced to the market last year, the Apisolex excipient is a polyamino-acid polymer designed for parenteral applications. The use of the Apisolex excipient has been proven to increase the solubility of active p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters